References

Prostatic carcinoma

10.1056/nejm197904123001504 · 1968 · External reference

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

10.1200/jco.1985.3.6.827 · 1985 · External reference

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

10.1002/(sici)1097-0142(19960315)77:6<1144::aid-cncr21>3.0.co;2-0 · 1996 · External reference

Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs

1988 · External reference

Is there evidence that chemotherapy is of benefit to patients with carcinoma of prostate?

10.1200/jco.1985.3.7.1013 · 1985 · External reference

Immunological factors which influence response to immunotherapy in malignant melanoma

1970 · External reference

Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis

10.1126/science.172.3980.271 · 1971 · External reference

Activation of peritoneal macrophages by lysophosphatidylcholine

10.1016/0304-4165(85)90175-8 · 1985 · External reference

Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages

10.1007/bf00199358 · 1986 · External reference

Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation

10.3181/00379727-193-43011 · 1990 · External reference

Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids

1987 · External reference

Activation of macrophages by ether analogues of lysophospholipids

10.1007/bf00199146 · 1987 · External reference

Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues

1988 · External reference

Treatment of cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF) rapidly eradicates cancerous cells

2006 · External reference

Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers

2004 · External reference

Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol

10.1111/j.1365-2249.1990.tb05195.x · 1990 · External reference

Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D-binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages

10.4049/jimmunol.147.1.273 · 1991 · External reference

Vitamin D3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells

1991 · External reference

Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine

10.1038/icb.1993.29 · 1993 · External reference

Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophosphatidylcholine-treated lymphocytes

10.1073/pnas.88.19.8539 · 1991 · External reference

Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells

10.4049/jimmunol.151.5.2794 · 1993 · External reference

Roles of β-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages

10.1016/0165-2478(94)90214-3 · 1994 · External reference

Structural definition of a potent macrophage activating factor derived from vitamin D3 binding protein with adjuvant activity for antibody production

10.1016/s0161-5890(96)00081-8 · 1996 · External reference

Vitamin D and the immune system

1998 · External reference

Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients

1996 · External reference

Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients

1997 · External reference

Eradication of HIV by treatment of HIVinfected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF)

2004 · External reference

Structural modification of serum vitamin D3-binding protein and immunosuppression in HIV-infected patients

10.1089/aid.1995.11.1373 · 1995 · External reference

Pathogenic significance of α-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1

10.1089/aid.2006.22.262 · 2006 · External reference

Pathogenic significance of α-N-acetylgalactosaminidase found in the hemagglutinin of influenza virus

10.1016/j.micinf.2005.01.015 · 2005 · External reference

Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization

10.1046/j.1440-1711.1998.00748.x · 1998 · External reference

Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice

1999 · External reference

Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor

1997 · External reference

Immunotherapy of metastatic breast cancer patients with vitamin D-binding proteinderived macrophage activating factor (GcMAF)

10.1002/ijc.23107 · 2008 · External reference

Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers

1998 · External reference

Immunotherapy of metastatic colorectal cancer with vitamin D-binding proteinderived macrophage-activating factor, GcMAF

10.1007/s00262-007-0431-z · 2008 · External reference

The Second Stanford Conference on international standardization of PSA assays

10.1002/1097-0142(19950101)75:1<122::aid-cncr2820750120>3.0.co;2-y · 1995 · External reference

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen

10.1002/(sici)1097-0142(19960815)78:4<809::aid-cncr18>3.0.co;2-z · 1996 · External reference

Serum α-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of uterine cervix

10.1016/s0304-3835(00)00502-4 · 2000 · External reference

Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography

10.1016/0003-2697(86)90624-x · 1986 · External reference

Participation of serum proteins in the inflammation-primed activation of macrophages

10.1007/bf01534272 · 1994 · External reference

Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin

10.1128/iai.61.12.5388-5391.1993 · 1993 · External reference

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

10.1016/0003-2697(76)90527-3 · 1976 · External reference

Biology and biochemistry of proteinases in tumor invasion

10.1152/physrev.1993.73.1.161 · 1993 · External reference

Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate

10.1016/s0022-5347(17)38491-4 · 1991 · External reference

Extra prostatic localization of prostate acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland

10.1016/0046-8177(90)90146-v · 1990 · External reference

Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry

10.1097/00000478-199304000-00012 · 1993 · External reference

Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer

1995 · External reference

The Veteran's Administration Cooperative Urological Research Group: Histological grading and clinical staging of prostate carcinoma

1977 · External reference